Clinical trial
Chemotherapy Combination With Local Radiotherapy and rhGM-CSF for Oligometastatic Stage IV NSCLC Patients Without Progression After First-line Chemotherapy: a Prospective Randomized Controlled Study
NCT03489616 is registered in ClinicalTrials.gov with Shandong Cancer Hospital and Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Chemotherapy Combination With Local Radiotherapy and rhGM-CSF for Oligometastatic Stage IV NSCLC Patients Without Progression After First-line Chemotherapy: a Prospective Randomized Controlled Study
- Lead sponsor
- Shandong Cancer Hospital and Institute
- Phase
- Not applicable
- Overall status
- Unknown status
- Start date
- January 15, 2018
- Completion date
- December 31, 2019
- Enrollment
- 45 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.